Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.73 |
| ▸ | PDE2A | O00408 | 4/20 | 0.73 |
| ▸ | PDE8A | O60658 | 4/20 | 0.73 |
| ▸ | PDE5A | O76074 | 4/20 | 0.73 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.73 |
| ▸ | PDE11A | Q9HCR9 | 4/20 | 0.73 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.73 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.73 |
| ▸ | PDE9A | O76083 | 3/20 | 0.73 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245880 | 0.98 | PDE4A (0.75) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL18840664 | 0.90 | PDE4A (0.67) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL10201369 | 0.90 | PDE4A (0.67) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL18844313 | 0.89 | PDE4A (0.78) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL18844314 | 0.89 | PDE4A (0.78) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL8056136 | 0.89 | PDE4A (0.78) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL8046074 | 0.89 | PDE4A (0.76) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL8044916 | 0.89 | PDE4A (0.65) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL21143268 | 0.88 | PDE4A (0.72) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL16273436 | 0.88 | PDE4A (0.64) | PDE4APDE2APDE8APDE5APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375994-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10682355-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190192519-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-10183023-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| EP-1888534-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-1888534-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128453-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9624230-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624230-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9000001-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130018063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-20130018063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-20130018063-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-01-17 | — | — | US | disclosed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273750-B2 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | INTRA-CELLULAR THERAPIES, INC (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682355-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE2A 9/4885PDE8A 299/4885 |
| US-10183023-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE2A 9/4885PDE8A 299/4885 |
| US-20170128453-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE2A 14/4885PDE8A 215/4885 |
| US-20190192519-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE2A 14/4885PDE8A 215/4885 |
| US-20130018063-A1 | ORGANIC COMPOUNDS | PDE9A, PDE3A, PDE7A | PDE4A 6/4885PDE2A 7/4885PDE8A 25/4885 |
| US-20080188492-A1 | 7,8-dihydro-[1H or 2H]-imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one or 7,8,9-trihydro-[1H or 2H]-pyrimido[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one, substituted at the 1 or 2 position with C2-]alkyl, C3-9 cycloalkyl, heteroarylalkyl, or arylalkyl; phosphodiesterase 1 inhibitors; Parkinsons disease | PDE9A, PDE3A, PDE7A | PDE4A 8/4885PDE2A 6/4885PDE8A 20/4885 |
| US-20200375994-A1 | NOVEL USES | BDNF, CNTN1, DCX | PDE4A 27/4885PDE2A 14/4885PDE8A 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.